课题基金 / 基金详情

Repurposing of FDA-approved drugs as novel therapeutics for COVID-19

Repurposing of FDA-approved drugs as novel therapeutics for COVID-19
将 FDA 批准的药物重新用作 COVID-19 的新型疗法
批准号：
422708
负责人：
Wu Jian Hui
金额：
$34.82万
依托单位：
CIUSSS de Centre-Ouest-de-l'Ile-de-Montral-Jewish General
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-02-01 至 2022-02-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=422708&lang=en
关键词：
Binding-Site Matching Bret2 Assays Covid-19 Drug Repurposing In Silico Screening Inhibitor Of Rbd/Ace2 Mpro Inhibitors Plpro Inhibitors

项目摘要

项目成果

Wu Jian Hui的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Currently, there is no vaccine or effective therapeutics for COVID-19, which is caused by 2019-nCoV (now officially referred to as SARS-CoV-2). Tens of thousands of people get infected by SARS-CoV-2 and substantial percentage of them showed severe symptom
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of novel pan-inhibitors of the androgen receptor variants as effective therapeutics for castration-resistant prostate cancer
Novel bifunctional antiandrogens that suppress oncogenic activation of the androgen receptor in castration-resistant prostate cancer
Chemical inhibitors of androgen receptor splice variants lacking the ligand-binding domain as novel agents for castration-resistant prostate cancer